Institut National De La Sante Et De La Recherche Medicale

Université Paris Diderot-Paris 7

Université Paris 13

Inserm

Alain Meulemans

Didier Letourneur

Martine Jandrot-Perrus

Philippe Billiald

Frederic Chaubet

Jean-Baptiste Michel

Julien Muzard

Dominique Le Guludec

François Rouzet

Laure Bachelet

Laure Sarda

Martine Jandrot-perrus

Frédéric Chaubet

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Fucoidans as ligands for the diagnosis of degenerative pathologies

The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E (SEQ ID NO: 1) wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.

Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis

Growing community of inventors

Paris, France

Alain Meulemans